- Home
- INMB vs IMMP Comparison
INMB vs IMMP Comparison
Compare INMB & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- IMMP
- Stock Information
- Founded
- INMB 2015
- IMMP 1987
- Country
- INMB United States
- IMMP Australia
- Employees
- INMB N/A
- IMMP N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- IMMP Health Care
- Exchange
- INMB Nasdaq
- IMMP Nasdaq
- Market Cap
- INMB 176.5M
- IMMP 211.1M
- IPO Year
- INMB 2019
- IMMP N/A
- Fundamental
- Price
- INMB $7.32
- IMMP $1.54
- Analyst Decision
- INMB Strong Buy
- IMMP Buy
- Analyst Count
- INMB 3
- IMMP 2
- Target Price
- INMB $24.33
- IMMP $8.50
- AVG Volume (30 Days)
- INMB 272.9K
- IMMP 85.9K
- Earning Date
- INMB 05-08-2025
- IMMP 04-29-2025
- Dividend Yield
- INMB N/A
- IMMP N/A
- EPS Growth
- INMB N/A
- IMMP N/A
- EPS
- INMB N/A
- IMMP N/A
- Revenue
- INMB $14,000.00
- IMMP $3,019,249.00
- Revenue This Year
- INMB N/A
- IMMP N/A
- Revenue Next Year
- INMB N/A
- IMMP $20.28
- P/E Ratio
- INMB N/A
- IMMP N/A
- Revenue Growth
- INMB N/A
- IMMP 24.11
- 52 Week Low
- INMB $4.32
- IMMP $1.32
- 52 Week High
- INMB $12.72
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- INMB 46.72
- IMMP 42.49
- Support Level
- INMB $7.14
- IMMP $1.44
- Resistance Level
- INMB $7.78
- IMMP $1.56
- Average True Range (ATR)
- INMB 0.71
- IMMP 0.12
- MACD
- INMB 0.00
- IMMP -0.00
- Stochastic Oscillator
- INMB 54.59
- IMMP 39.29
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.